A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

Published:2016-12-21 Issue:3 Volume:35 Page:290-297
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Kyriakopoulos Christos E.,Braden Amy M.,Kolesar Jill M.,Eickhoff Jens C.,Bailey Howard H.,Heideman Jennifer,Liu Glenn,Wisinski Kari B.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-016-0418-8/fulltext.html

Reference34 articles.

1. Robinson DR, YM W, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19(49):5548–5557

2. Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8(3):161–173

3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925

4. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G, Targeting MET (2012) In cancer: rationale and progress. Nat Rev Cancer 12(2):89–103

5. Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68–73

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches;Current Molecular Medicine;2023-05-09

2. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?;Biomedicines;2022-08-29

3. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer;Critical Reviews in Oncology/Hematology;2022-08

4. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?;International Journal of Molecular Sciences;2021-09-23

5. Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach;Anti-Cancer Agents in Medicinal Chemistry;2021-07-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3